-
Cancer Management and Research
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Cancer Management and Research
(464,743) Views
Editor in Chief Kenan Onel, MD
1179-1322
PerspectivesIntegrative systems of genomic risk markers for cancer and other diseases: future of predictive medicine
Yuzhalin AE, Kutikhin AG
Cancer Management and Research 2012, 4:131-135
23 May 2012
Letter
Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma
Kapoor S
Cancer Management and Research 2012, 4:129-130
08 May 2012
Original Research
Axillary dissection in primary breast cancer: variations of the surgical technique and influence on morbidity
Wojcinski S, Nuengsri S, Hillemanns P, Schmidt W, Deryal M, Ertan K, Degenhardt F
Cancer Management and Research 2012, 4:121-127
27 April 2012
Original Research
Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin
Iwazawa J, Ohue S, Hashimoto N, Mitani T
Cancer Management and Research 2012, 4:113-119
19 April 2012
Case report
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormone-sensitive early breast cancer: a case study
Bryce J, Bauer M, Hadji P
Cancer Management and Research 2012, 4:105-111
29 March 2012
Original Research
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
Aitini E, Rossi A, Morselli P, Vivorio B, Bruschi A, Bottura C, Colombo GL.
Cancer Management and Research 2012, 4:99-103
27 March 2012
Original Research
Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study
Estevinho F, Soares M, Azevedo I, Queiroga H, Parente B, Brito U, Teixeira E, Sotto-Mayor R, Araújo A
Cancer Management and Research 2012, 4:91-97
13 March 2012
Review
Management of cutaneous T cell lymphoma: new and emerging targets and treatment options
Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C
Cancer Management and Research 2012, 4:75-89
12 March 2012
Review
Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy
Roberts SM, Bezinover DS, Janicki PK
Cancer Management and Research 2012, 4:67-73
24 February 2012
Original Research
Psychological and sexual disorders in long-term breast cancer survivors
Pumo V , Milone G, Iacono M, Rametta Giuliano S, Di Mari A, Lopiano C, Bordonaro S, Tralongo P
Cancer Management and Research 2012, 4:61-65
24 February 2012
Original Research
Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
Richhariya A, Qian Y, Zhao Y, Chung K
Cancer Management and Research 2012, 4:55-60
22 February 2012
Perspectives
C-type lectin receptors and RIG-I-like receptors: new points on the oncogenomics map
Kutikhin AG, Yuzhalin AE
Cancer Management and Research 2012, 4:39-53
24 February 2012
Perspectives
Inherited variation in pattern recognition receptors and cancer: dangerous liaisons?
Kutikhin AG, Yuzhalin AE
Cancer Management and Research 2012, 4:31-38
16 February 2012
Commentary
Are Toll-like receptor gene polymorphisms associated with prostate cancer?
Kutikhin AG, Yuzhalin AE
Cancer Management and Research 2012, 4:23-29
07 February 2012
Original Research
Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario
Diaz JA, Murillo MF
Cancer Management and Research 2012, 4:9-21
23 January 2012
Review
The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
Verschraegen C
Cancer Management and Research 2012, 4:1-8
18 January 2012
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University




